USDA Import BSE Restriction Waiver Sought For IVD Products
This article was originally published in The Gray Sheet
Executive Summary
FDA and AdvaMed will meet with USDA during the first week of September to discuss whether BSE import restrictions should apply to in vitro diagnostic (IVD) products that contain ruminant-derived materials
You may also be interested in...
USDA BSE Import Restrictions For IVDs Delayed To Allow Policy Discussion
Importers of bulk in vitro diagnostic products that contain ruminant-derived material from countries with bovine spongiform encephalopathy (BSE) risk will have an additional two months to convince USDA not to cancel their import certificates
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”